Aberdeen Group
COAG

Aberdeen Group’s Hemab Therapeutics COAG Stock Holding History

Aberdeen Group’s Portfolio COAG Stock Details COAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.91M Buy
+52,117
New +$1.44M ﹤0.01% 780

Other funds holding COAG

TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Aberdeen Group's COAG Position: Q2 2026 in Review

Aberdeen Group opened a new position in Hemab Therapeutics (COAG) in Q2 2026: 52,117 shares worth $1.91M. The stake represents ﹤0.01% of the portfolio and ranks #780 among its holdings.

4 funds tracked by Wall St. Rank hold COAG as of Q2 2026.

  • Aberdeen Group held 52,117 shares of Hemab Therapeutics worth $1.91M as of Q2 2026.
  • Hemab Therapeutics was a new Aberdeen Group position in Q2 2026.
  • Hemab Therapeutics made up ﹤0.01% of Aberdeen Group's portfolio in Q2 2026, its #780 holding.
  • 4 funds tracked by Wall St. Rank held Hemab Therapeutics as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.